Cipla Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2026, reporting record quarterly revenue of ₹7,119 crore, supported by strong growth across its India business and steady performance in key international markets. The company continued to strengthen its leadership in chronic therapies, expanded its product portfolio, and increased investments in research and development to support future growth.
The company’s One India business delivered its highest-ever quarterly sales, registering 12% year-on-year growth. Growth was led by the Branded Prescription business, which outperformed the Indian Pharmaceutical Market with 15.4% growth, supported by robust demand across respiratory, cardiology, urology and anti-diabetes therapies. Cipla also improved its chronic portfolio mix to 60.4%, reflecting its continued focus on high-value therapies.
Trade Generics maintained healthy momentum through strong distribution execution and the launch of three new products during the quarter. The Consumer Health business also delivered a steady performance, with flagship brands including Nicotex, Omnigel and Cipladine retaining leadership positions in their respective categories.
International operations continued to contribute significantly to overall performance. The North America business reported quarterly revenue of US$162 million, supported by new product launches and continued market expansion. During the quarter, Cipla commercially launched gVentolin following regulatory approval received earlier, while also introducing Nintedanib and Dapagliflozin, strengthening its presence in key therapeutic segments.The company expects sequential growth in North America over the coming quarters as production volumes increase and its product pipeline expands.
In South Africa, Cipla maintained its position as the second-largest prescription pharmaceutical company, with its private market business growing faster than the overall market. The Emerging Markets and Europe business generated quarterly revenue exceeding US$100 million, recording 5% year-on-year growth in dollar terms, reflecting consistent demand across multiple geographies.
Cipla continued to invest in innovation, with research and development expenditure rising 12.3% year-on-year to ₹486 crore, representing 6.8% of quarterly sales. The increased investment supported product development programs and regulatory filings across global markets. The company also maintained a strong financial position with a net cash balance of ₹9,494 crore, providing flexibility to invest in growth opportunities while meeting operational requirements.
Commenting on the results, Achin Gupta, Managing Director and Global CEO, said the company delivered strong growth across its focused markets during the quarter. He noted that the India business achieved record quarterly sales, while key therapies continued to outperform the market. He added that North America is expected to witness further sequential growth supported by upcoming product launches, while South Africa and Emerging Markets continue to deliver steady performance. The company remains focused on expanding its flagship brands, strengthening its product pipeline and advancing regulatory initiatives.
Established in 1935, Cipla operates across more than 80 countries with 46 manufacturing facilities producing over 1,500 products in more than 50 dosage forms. The company continues to strengthen its presence in India, North America, South Africa and other global markets while advancing its commitment to improving access to quality healthcare through innovation and affordable medicines.
